In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Drago, Lorenzo ^a   De Vecchi, Elena ^a   Nicola, Lucia ^a   Gismondo, Maria Rita ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM; OFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG DETERMINATION; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUTATION; NONHUMAN; PNEUMONIA; RESPIRATORY TRACT INFECTION; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DRUG THERAPY, COMBINATION; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; PNEUMONIA; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 35349017448     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-111     Document Type: Article

References (33)

1. Petti CA Fowler VG Jr Staphylococcus aureus bacteremia and endocarditis Cardiol Clin 2003, 21:219-233. 10.1016/S0733-8651(03)00030-4 12874895
2. Sista RR Oda G Barr J Methicillin-resistant Staphylococcus aureus infections in ICU patients Anesthesiol Clin North America 2004, 22:405-435. 10.1016/j.atc.2004.04.006 15325711
3. Palavecino E Community-acquired methicillin-resistant Staphylococcus aureus infections Clin Lab Med 2004, 24:403-418. 10.1016/ j.cll.2004.03.007 15177847
4. Fluit AC Wielders CL Verhoef J Schmithz FJ Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study J Clin Microbiol 2001, 39:3727-3732. 88419 11574603 10.1128/ JCM.39.10.3727-3732.2001
5. Jevons MP "Celbenin" - resistant staphylococci BMJ 1961, 1:124-125.
6. Eguia JM Chambers HF Community-acquired methicillin resistant Staphylococcus aureus: Epidemiology and potential virulence factors Curr Infect Dis Rep 2003, 5:459-466. 10.1007/s11908-003-0087-6 14642185
7. Fridkin SK Hageman JC Morrison M Sanza LT Como-Sabetti K Jernigan JA Harriman K Harrison LH Lynfield R Farley MM Active Bacterial Core Surveillance Program of the Emerging Infections Program Network Methicillin-resistant Staphylococcus aureus disease in three communities N Engl J Med 2005, 352:1436-1444. 10.1056/NEJMoa043252 15814879
8. Spellberg B Powers JH Brass EP Miller LG Edwards JE Jr Trends in antimicrobial drug development: Implications for the future Clin Infect Dis 2004, 38:1279-1286. 10.1086/420937 15127341
9. Chopra I Antibiotic resistance in Staphylococcus aureus: Concerns, causes and cures Expert Rev Anti Infect Ther 2003, 1:45-55. 10.1586/ 14787210.1.1.45 15482101
10. Stefani S Varaldo PE Epidemiology of methicillin-resistant staphylococci in Europe Clin Microbiol Infect 2003, 9:1179-1186. 10.1111/ j.1469-0691.2003.00698.x 14686982
11. Eliopoulos GM Synergism and antagonism Infect Dis Clin North Am 1989, 3:399-406. 2671129
12. Alvarez-Lerma F Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit Intensive Care Med 1996, 22:387-394. 10.1007/BF01712153 8796388
13. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 2005, 171:388-416. 10.1164/rccm.200405-644ST 15699079
14. National Committee for Clinical laboratory Standards Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Seventh Edition: Approved Standard M7-A6 NCCLS, Villanova, PA, USA 2003
15. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing Thirteenth Informational Supplement M 100-S 13 NCCLS, Villanova, PA, USA 2003
16. Eliopoulos GM Moellering RC Antimicrobial combinations Antibiotics in laboratory medicine Baltimore, The Williams & Wilkins Co Lorian V 1991:432-492.
17. Pankey GA Ashcraft DS In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa Antimicrob Agents Chemother 2005, 49:2959-2964. 1168659 15980375 10.1128/ AAC.49.7.2959-2964.2005
18. Odds FC Synergy, antagonism, and what the chequerboard puts between them J Antimicrob Chemother 2003, 52:1. 10.1093/jac/dkg301 12805255
19. Michéa Hamzehpour M Kahr A Pechàre JC In vitro stepwise selection of resistance to quinolones, ̀-lactams and amikacin in nosocomial Gram-negative bacilli Infection 22(Suppl 2):S105-110. 10.1007/ BF01793574 7927828
20. Kollef MH The importance of appropriate initial antibiotic therapy for hospital-acquired infections Am J Med 2003, 115:582-584. 10.1016/ j.amjmed.2003.09.002 14599641
21. Huang V Rybak MJ Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model Antimicrob Agents Chemother 2005, 49:302-308. 538893 15616309 10.1128/AAC.49.1.302-308.2005
22. Jacqueline C Navas D Batard E Miegeville AF Le Mabecque V Kergueris MF Bugnon D Potel G Caillon J In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 2005, 49:45-51. 538916 15616274 10.1128/AAC.49.1.45-51.2005
23. Grohs P Kitzis MD Gutmann L In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47(1):418-420. 12499229 12499229 148978 10.1128/ AAC.47.1.418-420.2003
24. Rand KH Houck HJ Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 2004, 48:2871-2875. 478518 15273094 10.1128/ AAC.48.8.2871-2875.2004
25. Lozniewski A Lion C Mory F Weber M In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis J Antimicrob Chemother 2001, 47:83-86. 10.1093/jac/47.1.83 11152435
26. Rochon-Edouard S Pestel-Caron M Lemeland JF Caron F In vitro synergistic effects of double and triple combinations of β-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains Antimicrob Agents Chemother 2000, 44:3055-3066. 101602 11036022 10.1128/AAC.44.11.3055-3060.2000
27. Thamlikitkul V Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method J Med Assoc Thai 1991, 74:669-674. 1839906
28. Barr JG Smyth ET Hogg GM In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis Eur J Clin Microbiol Infect Dis 1990, 9:804-809. 10.1007/BF01967378 2150814
29. Ackermann BH Vannier AM Eudy EB Analysis of vancomycin time kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response Antimicrob Agents Chemother 1992, 36:1766-1769. 192044 1416862
30. Watanakunalorn C In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin J Antimicrob Chemother 1990, 25:69-72. 10.1093/jac/25.1.69 2138602
31. Biavasco F Giovanetti E Montanari MP Lupidi R Varaldo PE Development of in-vitro resistance to glycopeptide antibiotics: Assessment in staphylococci of different species J Antimicrob Chemother 1991, 27:71-79. 10.1093/jac/27.1.71 1828799
32. Pfeltz RF Singh VK Schmidt JL Batten MA Baranyk CS Nadakavukaren MJ Jayaswal RK Wilkinson BJ Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds Antimicrob Agents Chemother 2000, 44:294-303. 89674 10639353 10.1128/AAC.44.2.294-303.2000
33. Schaaff F Reipert A Bierbaum G An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus Antimicrob Agents Chemother 2002, 46:3540-3548. 128741 12384362 10.1128/ AAC.46.11.3540-3548.2002